摘要:
Broadly, then, one aspect of the present invention is a functional optical material composed of a liquid crystal (LC) evidencing a pair of refractive indices (RI's) and a polymer in which the LC is dispersed. The refractive index (RI) of said polymer may be outside of the L C RI's by at least about 0.03. Another aspect of the present invention is a functional optical material composed of a liquid crystal (LC) and a polymer in which the LC is dispersed, wherein said LC is less than about 5% miscible in said polymer. A further aspect of the present invention is a functional optical material composed of a liquid crystal (LC) and a polymer in which the LC is dispersed, wherein the cladding contains not more than about 20 wt-% LC. In all of these embodiments, the functional optical material can be clad to an optical waveguide and can optionally contain a chromophore. In yet another aspect of the present invention, a functional optical waveguide is composed of a polymer having a refractive index, RIP and an optical waveguide clad having a refractive index, RIWG, wherein RIP is at least about 0.3% lower than RIWG under operating conditions of said clad optical waveguide.
摘要:
This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.
摘要:
The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease.
摘要:
This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.
摘要:
The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease.
摘要:
This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.